BiOrion runs two active development programs.

In the diagnostic imaging program BOT5035-i, Cardiscan®, the PDGF beta receptor binding bicyclic peptide is conjugated to the PET radionuclide 68-Gallium. Apart form heart fibrosis, BOT5035-i is primarily developed to identify patients with organ fibrosis, including lung fibrosis, hepatic fibrosis and kidney fibrosis, allowing disease monitoring therapeutic strategies.

 

In the imaging diagnostic BOT1711-i, Oncoloscan®, the PET radionuclide 68-Gallium is conjugated to the PDGF-ß-receptor binding single domain antibody (VHH).
In the targeted radiotherapeutic BOT1711-t, Oncoluthera ® the PET radionuclide 177-Lutetium is conjugated to the PDGF-ß-receptor binding single domain antibody (VHH).